|
|
 |
| Endothelial progenitor cells |
 |
|
Endothelial progenitor cells (EPCs)
Vascularization of tissues is a major challenge of tissue regeneration research. EPCs have been suggested to play an important role in postnatal neoangiogenesis and neovascularization. Therefore, EPCs have come into focus for the potential treatment of ischemic or injured tissue or the coating of scaffolds to increase biocompatibility of biomaterials. EPCs are defined by the expression of the markers CD34 and CD309 (VEGFR-2/KDR). These markers in combination with CD133 allow the distinction between early and mature EPCs in human.1,2 EPCs have been enriched according to the expression of CD34 or CD133 from different hematopoietic sources.1,3–6 CD133 is also known as a surface marker on hemangioblasts – the common progenitor of hematopoietic stem cells and EPCs7.
Miltenyi Biotec offers numerous products for EPC research.
Enrichment and analysis of EPCs and mature endothelial cells (ECs) according to the expression of various markers:
Levels of circulating EPCs (cEPCs) are considered as potential biomarker for the assessment of risk factors or progress in various diseases.
The EPC Enrichment and Enumeration Kit allows the enrichment of EPCs and subsequent enumeration by flow cytometry, based on the expression of CD133, CD34, and CD309 (VEGFR-2/KDR).
Cultivation and differentiation
microRNA and gene expression profiling kits and services
* PIQOR™ Microarrays Kits are not available in the US and Canada.
References
1. Peichev, M. et al. (2000) Blood 95: 952–958.
2. Rafii, S. and Lyden, D. (2003) Nat. Med. 9: 702–712.
3. Gehling, U. et al. (2000) Blood 95: 3106–3112. [934]
4. Suuronen, E. et al. (2006) Circulation. 114 (suppl. I): I-138–I-144.
5. Wu, X. et al. (2004) Am. J. Physiol. Heart Circ. Physiol. 287: H480–H487,
6. Taguchi, A. et al. (2004) J. Clin. Invest. 330–338
7. Loges, S. et al. (2004) Stem Cells Dev. 13: 229–242. |
|
|
|
|
|
| My favorites |
| Your current favorite list is empty. |
|